pregabalin (Rx) - Lyrica

 
 
 

Adult Dosing & Uses

Dosing Forms & Strengths

capsule: Schedule V

  • 25mg
  • 50mg
  • 75mg
  • 100mg
  • 150mg
  • 200mg
  • 225mg
  • 300mg

oral solution : Schedule V

  • 20mg/mL

Diabetic Peripheral Neuropathic Pain

Initial: 50 mg PO q8hr; may increase to 100 mg PO q8hr within 1 week; not to exceed 600 mg/day

Postherpetic Neuralgia

Initial: 150 mg/d PO divided q8-12hr; increase within 1 week

Recommended: 150-300 mg/d PO divided q8-12hr, increase within 1 week; not to exceed 600 mg/day

Fibromylagia

Initial: 150 mg/d PO divided q12hr; may increase to 300 mg/d PO divided q12hr within 1 week

Recommended: 300-450 mg/day divided q12hr

Epilepsy

Initial: 150 mg/d divided q8-12hr PO; may increase to 600 mg/day

Geriatric Dosing

Diabetic Peripheral Neuropathic Pain

  • Initial: 50 mg PO q8hr; may increase to 100 mg PO q8hr within 1 week; not to exceed 600 mg/day

Postherpetic Neuralgia

  • Initial: 150 mg/d PO divided q8-12hr; increase within 1 week
  • Recommended: 150-300 mg/d PO divided q8-12hr, increase within 1 week; not to exceed 600 mg/day

Fibromylagia

  • Initial: 150 mg/d PO divided q12hr; may increase to 300 mg/d PO divided q12hr within 1 week
  • Recommended: 300-450 mg/day divided q12hr

Epilepsy

  • Initial: 150 mg/d divided q8-12hr PO; may increase to 600 mg/day

Renal Impairment

CrCl 30-60 mL/min: give half dose

CrCl <30 mL/min: reduce further, see manufacturer's package insert

Next

Pediatric Dosing & Uses

Safety/efficacy not established

Previous
Next

Drug Interactions

Interaction Checker

pregabalin and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Dose-dependent; percentages according to highest reported

            >10%

            Ataxia

            Dizziness

            Peripheral edema

            Somnolence

            Tremors

            Weight gain

            1-10%

            Abnormal thinking

            Accidental injury

            Asthenia

            Blurry vision

            Confusion

            Euphoria

            Incoordination

            Pain

            Constipation

            Xerostomia

            Postmarketing Reports

            Headache

            Nausea

            Diarrhea

            Gynecomastia and breast enlargement

            Previous
            Next

            Contraindications & Cautions

            Contraindications

            Hypersensitivity

            Cautions

            Discontinue gradually over at least 1 week

            History of angioedema, concurrency with drugs associated with angioedema risk (eg, ACEIs)

            Increased risk of angioedema, peripheral edema, dizziness, somnolence and weight gain

            Potential risk of male-mediated teratogenicity

            May impair ability to drive or perform hazardous tasks

            See FDA Warning on potential suicidal behavior

            Previous
            Next
            View Category Definitions

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: Do not nurse

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            Previous
            Next

            Pharmacology

            Mechanism of Action

            Precise mechanism unknown; binds to a subunit of voltage-gated calcium channels in CNS; may inhibit excitatory neurotransmitter release.

            Pharmacokinetics

            Bioavailability: >90%

            Half-Life, Elimination: 6.3 hr

            Peak Plasma Time: 1.5 hr

            Vd: 0.5 L/kg

            Protein Bound: None

            Metabolism: Minimal

            Excretion: Urine

            Previous
            Next

            Pricing & Images

            Previous
            Next
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
            This website also contains material copyrighted by 3rd parties.

            DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.